CHMP draft Guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products

Bioindustry Perspective

Dr Christiane Abouzeid

EMEA Workshop, 12 June 2007
Comments on draft guideline

• We support the development of the CHMP guideline

• There should be clear differentiation between chemical drugs and biologicals

• Not every new monoclonal antibody is a high-risk medicinal product

• Differentiation between different types of MAbs – antagonists versus agonists
Comments on draft guideline (continued)

• Manufacturing perspective:
  • Quality requirements should be based on stage of development
  • Otherwise, significant costs and delays will result if there are increased expectations regarding product characterisation

• More detailed guidance should be provided on the calculation of the first dose in man and subsequent dose escalation

• Clarification regarding the use of an independent drug safety monitoring board
Scope of the guideline

• The draft guideline is too general
• The scope of this guideline should be re-considered
• There are two possibilities:
  • First, the guideline covers all first-in-man studies and should focus on risk mitigation strategies
  • Second, the guideline covers only first-in-man studies for high risk products. In this case, we need to define what "high risk" is?
Definition of potential high-risk IMP

• ANY first in class compound could be caught in this definition

• If the definition of high-risk products is applied too widely this could have a detrimental effect on innovation

• We recommend that the definition of “high-risk medicinal product” is based on well defined criteria
In summary

The first-in-man clinical trials guideline will help to establish clear expectations of the data requirements for both applicants and regulatory agencies.